Lead Product(s) : ABT-301,Tislelizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : BeiGene
Deal Size : Undisclosed
Deal Type : Collaboration
Anbogen, BeiGene Collaborate on Colorectal Cancer Combo Therapy in Taiwan
Details : The collaboration will evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with BeiGene's anti-PD-1 antibody Tevimbra (tislelizumab), in pMMR or MSS metastatic colorectal cancer.
Product Name : ABT-301
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 27, 2024
Lead Product(s) : ABT-301,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : BeiGene
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Ainos and Merdury will evaluate the feasibility of Merdury's potential investment and participation in the completion of a Phase 3 clinical trial of the Company's Veldona (interferon alfa) drug candidate for treatment of oral warts i...
Product Name : Veldona
Product Type : Protein
Upfront Cash : Undisclosed
March 14, 2023
Lead Product(s) : Foslinanib,Sorafenib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : TaiRx
Deal Size : Undisclosed
Deal Type : Partnership
Bora Pharmaceuticals Partners with TaiRx
Details : CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific fact...
Product Name : CVM-1118
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 27, 2022
Lead Product(s) : Foslinanib,Sorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : TaiRx
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Antroquinonol
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Antroquinonol outperformed the other listing drugs for the treatment of relapsed acute myeloid leukemia in its Phase 2 clinical trial. 80% of patients showed that their blasts count were less than 5%. 90% of patients did not need blood transfusion during...
Product Name : Hocena
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
November 26, 2020
Lead Product(s) : Antroquinonol
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable